Natural killer cell

Cabaletta Bio Announces Presentation of Preclinical Data Showing Specific CAAR T Activity against Anti-MuSK Expressing B Cells

Monday, October 7, 2019 - 2:00pm

CAAR T cell therapy has the potential to target the pathogenic B cells producing autoantibodies to MuSK while sparing healthy B cells.

Key Points: 
  • CAAR T cell therapy has the potential to target the pathogenic B cells producing autoantibodies to MuSK while sparing healthy B cells.
  • For the preclinical study being presented, investigators generated CAARs expressing MuSK as an extracellular decoy on the surface of T cells.
  • These CAARs were observed to direct T cell cytotoxicity toward B cells expressing anti-MuSK antibodies resulting in their destruction.
  • Chimeric AutoAntibody Receptor (CAAR) T cells are designed to selectively bind and eliminate only disease-causing B cells, while sparing the normal B cells that are essential for human health.

GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

Thursday, October 3, 2019 - 3:05pm

Research findings from Dr. Schacker's and Dr. Miller's laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE.

Key Points: 
  • Research findings from Dr. Schacker's and Dr. Miller's laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE.
  • Peripheral blood mononuclear cells (T-cells, B-cells, NK cells and monocytes) from healthy donors incubated with the HIV-TriKE showed marked increases in immune cell activation in NK cell, CD4 T-cell and CD8 T-cell population subsets.The HIV-TriKE also induced NK cell proliferation, and demonstrated the ability in vitro to reactivate and kill HIV-infected T-cells.
  • HIV infected individuals remain infected for the rest of their lives.The challenge in the HIV field is to kill virus infecting a patient's T-cells, and destroy virus hiding in sanctuary reservoir sites within the body.
  • TriKE is a trademark of GT Biopharma, Inc.
    Dr. Miller also serves as Consulting Chief Medical Officer of GT Biopharma, Inc.

GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

Thursday, October 3, 2019 - 3:05pm

Research findings from Dr. Schacker's and Dr. Miller's laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE.

Key Points: 
  • Research findings from Dr. Schacker's and Dr. Miller's laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE.
  • Peripheral blood mononuclear cells (T-cells, B-cells, NK cells and monocytes) from healthy donors incubated with the HIV-TriKE showed marked increases in immune cell activation in NK cell, CD4 T-cell and CD8 T-cell population subsets.The HIV-TriKE also induced NK cell proliferation, and demonstrated the ability in vitro to reactivate and kill HIV-infected T-cells.
  • HIV infected individuals remain infected for the rest of their lives.The challenge in the HIV field is to kill virus infecting a patient's T-cells, and destroy virus hiding in sanctuary reservoir sites within the body.
  • TriKE is a trademark of GT Biopharma, Inc.
    Dr. Miller also serves as Consulting Chief Medical Officer of GT Biopharma, Inc.

2019 Natural Killer Cells Therapeutics Report: Market to Grow from $1.4 Billion in 2018 to $5.1 Billion by 2026

Tuesday, October 1, 2019 - 12:27pm

According to the report, the global natural killer cells therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026.

Key Points: 
  • According to the report, the global natural killer cells therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026.
  • By therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies.
  • Depending on end user, the global natural killer cells therapeutics market is classified into hospitals, research centers & institutes, and others.
  • The global natural killer cells therapeutics market is highly competitive, and the prominent players in the market have adopted various strategies for garnering maximum market share.

Global Natural Killer Cells Therapeutics Market Analysis, 2018-2026 - Segmented by Therapeutics, Application, End-user and Region - ResearchAndMarkets.com

Tuesday, October 1, 2019 - 12:45pm

By therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies.

Key Points: 
  • By therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies.
  • Depending on end user, the global natural killer cells therapeutics market is classified into hospitals, research centers & institutes, and others.
  • The global natural killer cells therapeutics market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • The global natural killer cells therapeutics market is highly competitive, and the prominent players in the market have adopted various strategies for garnering maximum market share.

Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer

Wednesday, September 18, 2019 - 1:00pm

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced the promotion of Nadir Mahmood, Ph.D., to the newly-created position of chief business officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, today announced the promotion of Nadir Mahmood, Ph.D., to the newly-created position of chief business officer.
  • Nadir has been an instrumental leader within our organization, said Paul Hastings, president and chief executive officer of Nkarta.
  • I am delighted to announce his promotion to chief business officer and look forward to his continued contributions to our success.
  • Nkarta Therapeutics was founded on the proprietary, robust and well characterized Natural Killer (NK) cell expansion technology pioneered by Dr. Dario Campana.

INmune Bio Invited to Speak on Company’s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress

Tuesday, September 17, 2019 - 2:05pm

Dr. Tesi will also discuss the results of the Phase I trial for INmune Bios drug candidate, INB03 in patients with advanced cancer.

Key Points: 
  • Dr. Tesi will also discuss the results of the Phase I trial for INmune Bios drug candidate, INB03 in patients with advanced cancer.
  • Wednesday, September 25 at 1:45 p.m.
    "What do Tumor Cells do to NK Cells?
  • INmune Bio, Inc. is a publicly traded (NASDAQ: INMB ) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease.
  • Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties.

NKMax America Announces New cGMP Manufacturing Facility for Production of SNK Cell Therapy

Monday, September 9, 2019 - 7:28pm

The new facility will house the U.S. operations for NKMax and includes administrative offices, a CLIA-certified, CAP-accredited clinical laboratory in addition to cGMP manufacturing capabilities.

Key Points: 
  • The new facility will house the U.S. operations for NKMax and includes administrative offices, a CLIA-certified, CAP-accredited clinical laboratory in addition to cGMP manufacturing capabilities.
  • The flagship facility represents NKMax's commitment to meeting production demands for the SNK cell therapy clinical trials and ultimately for commercial manufacturing.
  • "The new GMP facility builds on our technical capabilities and rapid progress towards advancing NK cell therapies," commented Stephen Chen, MBA, CTO of NKMax America.
  • NKMax America, Inc. is a biotech company specializing in both autologous and allogenic Natural Killer (NK) cell therapy utilizing proprietary cell expansion and cell activation technology.

Juntendo University Research: IPS Based Approach for Treating Virus-induced Tumors

Monday, September 9, 2019 - 10:08am

Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.

Key Points: 
  • Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.
  • Since ENKL tumors are commonly infected with the Epstein-Barr virus (EBV), T-cells recognize these tumor cells by the presence of viral proteins.
  • T-cells from patients' blood, which were accustomed to identifying ENKL tumors, were first collected and then genetically modified into stem cells.
  • Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.

Juntendo University Research: IPS Based Approach for Treating Virus-induced Tumors

Monday, September 9, 2019 - 10:00am

Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.

Key Points: 
  • Now, researchers at Juntendo University have created "customized" cells that show promise in reducing the size of tumors in model mouse experiments.
  • Since ENKL tumors are commonly infected with the Epstein-Barr virus (EBV), T-cells recognize these tumor cells by the presence of viral proteins.
  • T-cells from patients' blood, which were accustomed to identifying ENKL tumors, were first collected and then genetically modified into stem cells.
  • Today, Juntendo University continues to pursue innovative approaches to international level education and research with the goal of applying the results to society.